Relamorelin (TFA)
- Availability: 24/48H Stock Items & 2 to 6 Weeks non Stock Items.
- Dry Ice Shipment: No


Relamorelin (TFA)
UNSPSC Description:
Relamorelin (RM-131) TFA, a pentapeptide ghrelin analog, is a selective ghrelin/growth hormone secretagogue receptor (GHSR) agonist with a Ki of 0.42 nM for GHS-1a receptor. Relamorelin TFA is centrally penetrant. Relamorelin TFA increases growth hormone levels and accelerates gastric emptying. Relamorelin TFA has the potential for cachexia, gastroparesis, and gastric/intestinal dysmobility disorders research[1][2][3][4][5].Target Antigen:
GHSRType:
PeptidesRelated Pathways:
GPCR/G ProteinApplications:
Metabolism-protein/nucleotide metabolismField of Research:
Metabolic DiseaseAssay Protocol:
https://www.medchemexpress.com/relamorelin-tfa.htmlPurity:
99.81Solubility:
H2O : 100 mg/mL (ultrasonic)Smiles:
NC(C1(NC([C@@H](NC([C@H](NC([C@H](NC(C2CCNCC2)=O)CC3=CSC4=CC=CC=C34)=O)CC5=CNC6=CC=CC=C56)=O)CC7=CC=CC=C7)=O)CCNCC1)=O.OC(C(F)(F)F)=OMolecular Weight:
905.00References & Citations:
[1]DeBoer MD, et, al. Ghrelin treatment causes increased food intake and retention of lean body mass in a rat model of cancer cachexia. Endocrinology. 2007 Jun;148(6):3004-12.|[2]Fischer K, et, al. The Pentapeptide RM-131 Promotes Food Intake and Adiposity in Wildtype Mice but Not in Mice Lacking the Ghrelin Receptor. Front Nutr. 2015 Jan 12;1:31.|[3]Zatorski H, et, al. Relamorelin and other ghrelin receptor agonists - future options for gastroparesis, functional dyspepsia and proton pump inhibitors-resistant non-erosive reflux disease. J Physiol Pharmacol. 2017 Dec;68(6):797-805.|[4]Matthew Heckroth, et al. Nausea and Vomiting in 2021: A Comprehensive Update. J Clin Gastroenterol. 2021 Apr 1;55(4):279-299.|[5]Victor Chedid, et al. Relamorelin for the treatment of gastrointestinal motility disorders. Expert Opin Investig Drugs. 2017 Oct;26(10):1189-1197.Shipping Conditions:
Blue IceStorage Conditions:
-80°C, 2 years; -20°C, 1 year (Powder, sealed storage, away from moisture)Clinical Information:
Phase 3CAS Number:
2863659-22-5
